CBMU

The Center for Breakthrough Medicines (CBM) is a leading contract development and manufacturing organization (CDMO) specifically designed to enable the rapid development and commercialization of cell and gene therapies. Based in King of Prussia, Pennsylvania, the company operates one of the world's largest single-site cell and gene therapy manufacturing facilities, offering end-to-end services from process development to commercial production. CBM provides critical capabilities in viral vector manufacturing, cell processing, plasmid DNA production, and analytical testing. In 2023, the company was fully acquired by SK Pharmteco, a global CDMO, to strengthen its position in the advanced therapeutics market. CBM's mission is to accelerate the delivery of life-saving treatments to patients by overcoming manufacturing bottlenecks in the biotech industry.